Update on sporadic inclusion body myositis

Brain

Volumn 134, Issue 11, 2011, Pages 3141-3145

  Hohlfeld, Reinhard ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; METHOTREXATE; PLACEBO; PREDNISONE;

ASPIRATION; CACHEXIA; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DYSPHAGIA; EUTHANASIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; MUSCLE STRENGTH; MYOPATHY; NOTE; PALLIATIVE THERAPY; PRIORITY JOURNAL; RESPIRATORY FAILURE; SPORADIC INCLUSION BODY MYOSITIS;

EID: 81055133062     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr258     Document Type: Note

References (24)

1. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009; 80: 1186-93.
2. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16: 193-208. (Pubitemid 14062666)
3. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III: immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 1986; 19: 112-25. (Pubitemid 16114164)
4. Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51: 369-72. (Pubitemid 34206293)
5. Badrising UA, Maat-Schieman ML, van Houwelingen JC, van Doorn PA, van Duinen SG, van Engelen BG, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol 2005; 252: 1448-54. (Pubitemid 41803832)
6. Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000; 54: 1033-41. (Pubitemid 30151842)
7. Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al. Long-term observational study of sporadic inclusion body myositis in 136 patients. Brain 2011; 134: 3176-84.
8. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70: 418-24.
9. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJGM, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end-stage with major disabilities. Brain 2011; 134: 3167-75.
10. Dalakas MC. Review: an update on inflammatory and autoimmune myo-pathies. Neuropathol Appl Neurobiol 2011; 37: 226-42.
11. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-15. (Pubitemid 14062667)
12. Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010; 12: 221-8.
13. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-13.
14. Henriques-Pons A, Nagaraju K. Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol 2009; 21: 581-7.
15. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010; 20: 142-7.
16. Ivanidze J, Hoffmann R, Lochmuller H, Engel AG, Hohlfeld R, Dornmair K. Inclusion body myositis laser microdissection reveals differential up-regulation of ifn-gamma signaling cascade in attacked versus nonattacked myofibers. Am J Pathol 2011; 179: 1347-59.
17. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis: Observations in 40 patients. Brain 1989; 112: 727-47. (Pubitemid 19151167)
18. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endo-plasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52: 1824-35. (Pubitemid 40852891)
19. Nagaraju K, Raben N, Loeffler L, Rawat R, Cutting S, Thapliyal R, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibo-dies. Proc Natl Acad Sci USA 2000; 97: 9209-14. (Pubitemid 30626699)
20. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6: 620-31. (Pubitemid 46921056)
21. Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000; 55: 296-8. (Pubitemid 30604636)
22. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammation and APP in sporadic IBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008; 131: 1228-40.
23. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-42.
24. Verschuuren JJ, Badrising UA, Wintzen AR, Engelen B, van der Hoeven H, Hoogendijk JE. Inclusion body myositis. In: Emery A, editor. Diagnostic criteria for neuromuscular disorders. London: Royal Society of Medicine Press, European Neuromuscular Center; 1997. p. 81-4.